Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trial Details

Geo Regions

Category

Breast Cancer

CDK2 Inhibitor

PF-07104091 is an investigational compound. Its safety and efficacy have not been established.

Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060) is an investigational compound. Its safety and efficacy have not been established.

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Phase 1 /2

NCT05262400

Active Not-enrolling

Globe

Locations

United States, Argentina, Brazil, Bulgaria, China, Czechia, Mexico, South Africa, Spain

QR Code

Scan the QR code

for more information at clinicaltrials.gov

Share to an HCP Go to Patient Site Contact Us
Study design
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 1

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 2

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 3

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 4

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 5

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 2A

PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and Endocrine Therapy)

Intervention/Treatment

DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion

PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
Participant Group/Arm

EXPERIMENTAL: Part 2B

PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior endocrine therapy and up to 1 prior line of chemotherapy for advanced or metastatic disease and no prior treatment with any CDK4/6 inhibitor for advanced disease)

Intervention/Treatment

DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion

PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
Participant Group/Arm

EXPERIMENTAL: Part 2C

PF-07220060 + PF-07104091 + Letrozole (ER+/HER2- Breast Cancer with no prior treatment with any CDK4/6 inhibitor for advanced disease)

Intervention/Treatment

DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion

PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 6

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 7

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Participant Group/Arm

EXPERIMENTAL: Part 1 Dose Escalation - Dose Level 8

PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

Intervention/Treatment

DRUG: PF-07220060 + PF-07104091 combination dose escalation

PF-07104091 and PF-07220060 will be administered orally
Study design table for Clinical Trial
Key eligibility criteria
Inclusion criteria
Inclusion Criteria
  • Part 1: Breast Cancer (BC)
  • HR+, HER2- BC
  • Refractory HR-positive/HER2-positive BC
  • Part 1: Solid Tumors other than BC
  • Part 2:
  • HR-positive/HER2-negative BC
  • Lesion:
  • Part 1: evaluable lesion (including skin or bone lesion only)
  • Part 2: measurable lesion per RECIST v1.1
  • Prior systemic Treatment
  • Part 1: HR-positive/HER2-negative BC
  • At least 1 line of SOC, including CDK4/6 inhibitor therapy and Endocrine Therapy, for advanced or metastatic disease.
  • Prior chemotherapy in the metastatic setting is allowed.
  • Part 1: HR-positive/HER2-positive BC
  • At least 1 prior treatment of approved HER2 targeting therapy.
  • Part 1: Solid Tumors other than BC
  • Participants with no standard therapy available or for which no local regulatory approved standard therapy is available that would confer significant clinical benefit in the medical judgement of the investigator.
  • Part 2A: At least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and ET.
  • Parts 2B: At least 1 prior endocrine therapy for advanced or metastatic disease. Progression during treatment or within 12 months of completion of adjuvant endocrine therapy is acceptable.
  • Part 2B: Up to 1 prior line of chemotherapy for advanced/metastatic disease is allowed.
  • General Inclusion Criteria
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Adequate renal, liver, and bone marrow function
  • Resolved acute effects of any prior therapy to baseline severity
Exclusion criteria
  • All Study Parts: Permanent treatment discontinuation from prior CDK 4 and/or CDK2 inhibitor due to treatment related toxicity.
  • Part 2B and 1C: Prior treatment with any CDK 4/6 inhibitor, or SERDs (e.g. fulvestrant), or everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway for advanced disease.
  • Parts 2B and 2C: Prior treatment with any CDK4/6 inhibitor for advanced disease.
  • Parts 2B and 2C: Prior treatment with an investigational endocrine therapy for advanced disease.
  • Part 2C: Prior neoadjuvant or adjuvant treatment with a nonsteroidal aromatase inhibitor AI (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment.
  • Part 2C: Any prior systemic treatment for advanced disease.
  • Prior irradiation to \>25% of the bone marrow
  • Current use of drugs which have a risk for QTc prolongation
  • Current use or anticipated need for food or drugs that are known strong CYP3A4/5, strong UGT2B7 or UGT1A9 inhibitors or inducers
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
    • Participants with any other active malignancy within 3 years prior to enrollment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease
    • Major surgery within 4 weeks prior to study entry
    • Radiation therapy within 4 weeks prior to study entry.
    • Clinically important hypertension
    • Known or suspected hypersensitivity to PF-07220060, PF-07104091, letrozole, fulvestrant, or goserelin (or equivalent to induce chemical menopause if applicabl
  • Known abnormalities in coagulation. Anticoagulation with subcutaneous heparin or prophylactic doses of anticoagulant are allowed
  • Known active uncontrolled or symptomatic central nervous system (CNS) metastases
  • Active inflammatory GI disease
  • Current use or anticipated need for Proton Pump Inhibitors (PPI) within 14 days prior to first dose of the study intervention
  • Previous high-dose chemotherapy requiring stem cell rescue
  • Participants with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), and known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  • Other protocol specific exclusion criteria may apply
    • Key dates
    Study start date
    • March 2022
    Estimated Study Completion Date
    • August 2026
    Key endpoints
    Primary Outcome Measures
    Outcome Measure

    Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle

    Measure Description

    Number of participants with DLTs, which are typically Grade 3 or higher adverse events will be summarized by dose level

    Time Frame

    Cycle 1 (28 days)

    Outcome Measure

    Number of participants with treatment emergent adverse events (AEs)

    Measure Description

    Time Frame

    From baseline until end of study treatment or study completion (approximately 2 years)

    Outcome Measure

    Incidence of participants with clinical laboratory abnormalities

    Measure Description

    Time Frame

    From baseline until end of study treatment or study completion (approximately 2 years)

    Outcome Measure

    Number of participants with vital signs abnormalities

    Measure Description

    Time Frame

    From baseline until end of study treatment or study completion (approximately 2 years)

    Outcome Measure

    Number of participants with corrected QT (QTc) interval

    Measure Description

    Determine the effect of the drug on QT prolongation. The number and percentage of participants who experienced QT interval prolongation will be summarized by dose level

    Time Frame

    From baseline until end of study treatment or study completion (approximately 2 years)

    Primary Outcome Measures table for Clinical Trial
    Secondary Outcome Measures:
    Outcome Measure

    Maximum plasma concentration (Cmax) of PF-07220060 and PF-07104091 together after a single dose and multiple dose

    Measure Description

    Time Frame

    Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

    Outcome Measure

    Time to maximum plasma concentration (Tmax) of PF-07220060 and PF-07104091 together after a single dose and multiple dose

    Measure Description

    Time Frame

    Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

    Outcome Measure

    Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-07220060 and PF-07104091 together

    Measure Description

    Time Frame

    Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

    Outcome Measure

    Objective response rate (ORR) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    Measure Description

    Percentage of participants with a best ORR of complete response (CR) or partial response (PR) using RECIST 1.

    Time Frame

    From baseline through disease progression or study completion (approximately 2 years)

    Outcome Measure

    To evaluate the preliminary antitumor activity of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole by time to event endpoints

    Measure Description

    Time from first assessment of event endpoint to last assessment of using RECIST 1.1

    Time Frame

    From baseline through time to event on study or study completion (approximately 2 years)

    Outcome Measure

    Duration of Response (DoR) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    Measure Description

    DoR is defined as the time from first documentation of CR or PR to date of first documentation of progressive disease/pharmacodynamic (PD) or death due to any cause, whichever occurs first

    Time Frame

    From baseline through time to event on study or study completion (approximately 2 years)

    Outcome Measure

    Progression-Free Survival (PFS) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    Measure Description

    PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause

    Time Frame

    From baseline through time to event on study or study completion (approximately 2 years)

    Outcome Measure

    Time to Progression (TTP) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    Measure Description

    TTP is defined as the time from start date of treatment to the date of the first documentation of PD

    Time Frame

    From baseline through time to event on study or study completion (approximately 2 years)

    Secondary Outcome Measures table for Clinical Trial
    Number of participants

    192

    Collaborators and investigators

    Sponsor: Pfizer

    Collaborator: None

    This information is current as of November 18th 2024.

    Contact Us
    Close

    For more information, call or email the Pfizer Clinical Trial Contact Center:

    1-800-887-7002 Email us

    When calling, please reference this study number:

    More Information Close NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT05262400